CTOs on the Move

Jeiven Pharmaceutical Consulting

www.jeiven.com

 
Jeiven Pharmaceutical Consulting is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.jeiven.com
  • 6 Jacobs Ln
    Scotch Plains, NJ USA 07076
  • Phone: 908.233.4508

Executives

Name Title Contact Details

Similar Companies

Absolute Biotech

Absolute Biotech is a company that specializes in antibody reagents, kits, and services, adding value to existing antibodies through annotation, validation, sequencing, engineering, and recombinant manufacturing.

Sharp

Sharp works across the world to create unique commercial and clinical packaging solutions for the pharmaceutical and biotechnology industry. We are made up of two dynamic international divisions, Sharp Packaging Solutions and Sharp Clinical Services. Together our 1,600-strong team works from state-of-the-art facilities in the United States, United Kingdom, Belgium and the Netherlands.

Merrimack

At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.

Zydus Pharmaceuticals (USA)

Zydus Pharmaceuticals (USA) is a Pennington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.